promo_leaderboard Ad
‹ All stocks
MDGL

Madrigal Pharmaceuticals

MDGL · NASDAQ · Healthcare
$418.31
▼ $5.65 (-1.33%)
$376.05 $421.77 $467.49 $513.21 $418.31 Sep 2026 Oct 2026 Nov 2026
Day range
$413.36 – $422.99
Year range
$353.54 – $615.00
Open
$419.63
Previous close
$423.96
Market cap
$9.72B
Volume (24h)
$15.3K
Volume (52w)
$6.41M
Performance
7D
▼ -3.30%
1M
▼ -6.44%
3M
▼ -22.56%
6M
▼ -18.55%
1Y
▼ -24.41%
YTD
▼ -29.56%
3Y
▲ 120.11%
5Y
▲ 401.87%
All-time
▲ 31.48%
Key statistics
P/E ratio
-69.95
EPS (TTM)
$-5.98
Dividend yield
—
Dividend (TTM)
—
Payout ratio
—
Shares outstanding
23.2M
About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.

Visit website
Country: United States of America
Related news
More in Healthcare